EGFR Mutation Positive Non-small Cell Lung Cancer study: NXP900 vs Osimertinib
Official title Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
ClinicalTrials.gov ID: NCT07315113
What this study is testing
What is NXP900?
NXP900 is an investigational oral medicine being studied for EGFR mutation positive non-small cell lung cancer. It is designed to block specific proteins called SRC family kinases that may help cancer cells grow.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to find the safest dose of a new medicine called NXP900 when taken with osimertinib.
- Who it's for
- The study is looking for adults with advanced non-small cell lung cancer that has an EGFR gene mutation.
- What's involved
- Participants will take NXP900 and osimertinib and visit the clinic for regular health checks and blood tests.
- Time commitment
- The study duration is not specified in the provided text.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Provide written informed consent.
- 18 years old or older.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Unresectable, metastatic or locally advanced EGFR-mutated NSCLC.
- Prior treatment with osimertinib as first or second line, as single agent or in combination with chemotherapy, in the metastatic or locally advanced...
You likely can't join if
- Subject's cancer has a known oncogenic driver alteration other than EGFR.
- Known EGFR mutations that cause resistance to osimertinib
- Known human epidermal growth factor receptor 2 (HER2) overexpression
- Any contraindications to treatment with osimertinib
The study team makes the final eligibility decision.
Where it is enrolling
- Calverton, Maryland, United States
- Eugene, Oregon, United States
- Pittsburgh, Pennsylvania, United States
- Houston, Texas, United States
- Fairfax, Virginia, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Calverton, Maryland, United States; Eugene, Oregon, United States; Pittsburgh, Pennsylvania, United States; Houston, Texas, United States; Fairfax, Virginia, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.